Residency · Residency · Internal Medicine

Dyslipidemia and Cardiovascular Risk Reduction

Start here

Alright, intern. You look like you’ve been running all night, so let’s make this simple. Imagine a 55-year-old guy, Mr. Henderson, who just had a heart attack. He’s lying there in bed, and his cardiologist tells him his low-density lipoprotein cholesterol, or "bad" cholesterol, was way too high. Now, your job is to make sure this doesn't happen again. The first, most crucial step is a high-intensity statin. Think of statins like a shield that protects his arteries from further damage. We know, without a shadow of a doubt, that getting that LDL-C down significantly reduces his risk of another event. Don't worry too much about hitting an exact number right away; the goal is just to reduce it as much as safely possible, ideally by 50% or more. This is secondary prevention – he’s already had an event, so we go all in.

Now, what if Mr. Henderson tells you he can't tolerate statins because of muscle aches? That’s where things get a bit more nuanced. First, you gently remind him that many times, those aches are what we call a "nocebo" effect – basically, his brain anticipating side effects, even with a placebo. We try a different statin, maybe a lower dose, or even dose it every other day. But if he genuinely can’t take them, we have other tools. We can add ezetimibe, which helps his gut absorb less cholesterol. If his LDL-C is still too high, we can bring in a PCSK9 inhibitor, like evolocumab or alirocumab, which are powerful injections that drop LDL-C by another 50-60%. And for those truly statin-intolerant folks, there’s even a new kid on the block, bempedoic acid, that works differently in the liver and has been shown to reduce heart attacks. The bottom line is, we have many ways to get his cholesterol down and protect his heart, even if the first path isn't perfect. We keep pushing until we achieve the lowest LDL-C possible for secondary prevention.

Introduction

Dyslipidemia, particularly elevated low-density lipoprotein cholesterol (LDL-C), is a causal and modifiable risk factor for atherosclerotic cardiovascular disease (ASCVD). Statin therapy remains the cornerstone of treatment, but the therapeutic landscape has expanded significantly with the addition of ezetimibe, PCSK9 inhibitors, bempedoic acid, and inclisiran. A risk-based approach guides treatment intensity and target selection.

Lipid Physiology and Atherogenesis

• LDL particles penetrate the endothelium, undergo oxidation, and trigger an inflammatory cascade leading to foam cell formation and plaque development
• Mendelian randomization studies confirm that lifelong exposure to lower LDL-C reduces ASCVD risk proportionally
• "Lower is better": each 1 mmol/L (39 mg/dL) reduction in LDL-C reduces major vascular events by approximately 22% (CTT meta-analysis)
• Non-HDL cholesterol captures all atherogenic particles (LDL, VLDL, IDL, Lp(a)) and may be a superior treatment target
• Apolipoprotein B (ApoB): one molecule per atherogenic particle; increasingly recognized as the best measure of atherogenic burden

Cardiovascular Risk Assessment

• 10-year ASCVD risk: Pooled Cohort Equations (PCE) estimate risk of first MI, stroke, or CV death
• Risk enhancers: family history of premature ASCVD, metabolic syndrome, CKD, chronic inflammatory conditions (RA, psoriasis, HIV), South Asian ancestry, elevated Lp(a), elevated hsCRP
• Coronary artery calcium (CAC) score: useful when risk-based decision is uncertain (borderline/intermediate risk); CAC = 0 generally supports deferring therapy

Statin Therapy

Indications for Statin Initiation (2018 ACC/AHA)

• Clinical ASCVD (secondary prevention): high-intensity statin for all
• LDL-C >= 190 mg/dL (primary hypercholesterolemia): high-intensity statin without risk calculation
• Diabetes, age 40-75: at least moderate-intensity statin; high-intensity if multiple risk factors
• 10-year ASCVD risk >= 7.5%: moderate-to-high intensity statin after clinician-patient risk discussion

High-Intensity vs. Moderate-Intensity

Statin Safety

• Myalgias: reported in 5-10% but nocebo effect is significant (SAMSON trial: two-thirds of statin-attributed symptoms also occurred with placebo)
• Hepatotoxicity: rare; routine LFT monitoring no longer recommended
• New-onset diabetes: modest risk (1 additional case per 255 patients treated for 4 years); cardiovascular benefit far outweighs risk
• Drug interactions: avoid simvastatin > 20 mg with amlodipine or diltiazem; rosuvastatin preferred with fewer CYP3A4 interactions

Non-Statin Therapies

Ezetimibe

• Blocks intestinal cholesterol absorption via NPC1L1 transporter
• Additional LDL-C reduction of 15-20% when added to statin
• IMPROVE-IT: ezetimibe + simvastatin reduced MACE vs. simvastatin alone in post-ACS patients

PCSK9 Inhibitors

• Evolocumab (Repatha) and alirocumab (Praluent): monoclonal antibodies given subcutaneously every 2-4 weeks
• LDL-C reduction: 50-60% on top of maximally tolerated statin
• FOURIER: evolocumab reduced MACE by 15%; greatest benefit when LDL-C lowered below 20 mg/dL
• ODYSSEY OUTCOMES: alirocumab reduced MACE and all-cause mortality in post-ACS patients
• Indicated for ASCVD patients not at LDL-C goal despite maximally tolerated statin + ezetimibe

Inclisiran

• Small interfering RNA (siRNA) targeting hepatic PCSK9 mRNA synthesis
• Administered subcutaneously twice yearly after initial loading doses
• LDL-C reduction approximately 50%; cardiovascular outcomes trial (ORION-4) ongoing
• Practical advantage: eliminates adherence burden of biweekly injections

Bempedoic Acid

• ACL inhibitor: blocks cholesterol synthesis upstream of HMG-CoA reductase
• Prodrug activated in the liver (not in skeletal muscle, hence no myalgia)
• CLEAR Outcomes: reduced MACE by 13% in statin-intolerant patients
• LDL-C reduction: 18-25% as monotherapy; available in fixed-dose combination with ezetimibe

Triglycerides and Residual Risk

• Hypertriglyceridemia (>= 500 mg/dL): risk of pancreatitis; treat with fibrates, omega-3 fatty acids, dietary modification
• REDUCE-IT: icosapent ethyl (EPA) 4 g/day reduced MACE by 25% in statin-treated patients with triglycerides 135-499 mg/dL
• STRENGTH: carboxylic acid omega-3 (EPA+DHA) showed no benefit, suggesting the EPA component is key
• Lp(a): genetically determined, not meaningfully lowered by statins; emerging therapies (olpasiran, lepodisiran) show > 90% Lp(a) reduction

LDL-C Treatment Thresholds

• Very high-risk ASCVD: LDL-C goal < 55 mg/dL (ESC/EAS) or >= 50% reduction (ACC/AHA); add ezetimibe, then PCSK9 inhibitor if not at goal
• High-risk primary prevention (LDL >= 190 or diabetes with risk factors): target >= 50% reduction
• Moderate-risk primary prevention: shared decision-making; consider risk enhancers and CAC score

Key Clinical Pearls

• Statins remain the foundation of ASCVD risk reduction; address statin hesitancy with evidence from the SAMSON and StatinWISE trials showing high nocebo rates
• In secondary prevention, the goal is maximal LDL-C lowering; there is no lower threshold below which benefit ceases
• Bempedoic acid is an important option for truly statin-intolerant patients with proven MACE reduction
• Check Lp(a) at least once in every patient; it is an independent, causal risk factor not captured by standard lipid panels

References

1. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC Guideline on Management of Blood Cholesterol. Circulation. 2019;139(25):e1082-e1143.
2. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER). N Engl J Med. 2017;376(18):1713-1722.
3. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients (CLEAR Outcomes). N Engl J Med. 2023;388(15):1353-1364.
4. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular Risk Reduction with Icosapent Ethyl (REDUCE-IT). N Engl J Med. 2019;380(1):11-22.

For the intern

At 3am, your priorities are acute lipid crises: severe hypertriglyceridemia (>1000 mg/dL) with abdominal pain suggesting pancreatitis requires immediate NPO status, IV fluids, and consultation. Check lipase and consider insulin infusion if triglycerides exceed 1000-2000 mg/dL. Everything else can wait until morning rounds. Routine dyslipidemia management—starting statins, adjusting doses, ordering coronary artery calcium (CAC) scoring—is not urgent. If a patient has statin-associated muscle symptoms, document severity and timing, but therapeutic decisions happen during daylight hours with attending input. Never discontinue a statin at 3am unless rhabdomyolysis is confirmed (check creatine kinase if clinical suspicion exists).

Common pitfalls

• Starting high-intensity statins without considering drug interactions: simvastatin exceeding 20 mg with amlodipine or diltiazem risks myopathy. Choose rosuvastatin or atorvastatin instead.
• Abandoning statins prematurely for subjective myalgias: two-thirds of statin-attributed symptoms occur with placebo (SAMSON trial). Trial a different statin or reduced dosing before declaring intolerance.
• Forgetting that atherosclerotic cardiovascular disease (ASCVD) means maximum intensity therapy: patients with prior myocardial infarction, stroke, or revascularization need high-intensity statins plus ezetimibe, targeting low-density lipoprotein cholesterol (LDL-C) below 55 mg/dL. This isn't optional.
• Ordering routine liver function tests on statins: guidelines abandoned routine monitoring years ago. Check baseline transaminases, then only if symptoms suggest hepatotoxicity.

Make it stick

Imagine Mrs. Rodriguez, a 62-year-old with a history of hypertension and well-controlled type 2 diabetes. She had a non-ST elevation myocardial infarction (NSTEMI) six months ago, for which she received a stent. She’s on atorvastatin 40mg, but her last LDL-C was 85 mg/dL. You're reviewing her chart and see she still smokes. Your attending asks what your next step is. This is a clear case for maximizing her lipid-lowering therapy due to very high-risk atherosclerotic cardiovascular disease (ASCVD). You'd advocate for increasing her atorvastatin to 80mg, and if her LDL-C remains above 55 mg/dL, consider adding ezetimibe, then a PCSK9 inhibitor. Don't forget smoking cessation counseling.

If you remember one thing

For patients with established atherosclerotic cardiovascular disease, the goal is maximal low-density lipoprotein cholesterol (LDL-C) lowering, ideally targeting below 55 mg/dL, utilizing high-intensity statins, ezetimibe, and PCSK9 inhibitors as needed. There is no lower limit to the benefit of LDL-C reduction in these patients.

Read this lecture as Markdown